Combined modality therapy with TRAIL or agonistic death receptor antibodies

• Published in: Cancer biology & therapy Vol. 11; no. 5; pp. 431 - 449
• Main Authors: Amm, Hope M., Oliver, Patsy G., Lee, Choo Hyung, Li, Yufeng, Buchsbaum, Donald J.
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.03.2011; Landes Bioscience
• Subjects: Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents - metabolism; Antineoplastic Agents - therapeutic use; Apoptosis; Binding; Biology; Bioscience; Calcium; Cancer; Cell; Combined Modality Therapy; Cycle; Humans; Landes; Molecular Targeted Therapy; Neoplasms - drug therapy; Neoplasms - metabolism; Organogenesis; Proteins; Receptors, TNF-Related Apoptosis-Inducing Ligand - agonists; Receptors, TNF-Related Apoptosis-Inducing Ligand - immunology; Receptors, TNF-Related Apoptosis-Inducing Ligand - metabolism; Review; Signal Transduction - drug effects; TNF-Related Apoptosis-Inducing Ligand - metabolism; TNF-Related Apoptosis-Inducing Ligand - therapeutic use

Molecularly targeted therapies, such as antibodies and small molecule inhibitors have emerged as an important breakthrough in the treatment of many human cancers. One targeted therapy under development is tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) due to its ability to induce ap...